|
|
The Effects of Danshen Chuanxiongqin Injection Combined with Trimetazidine on Electrocardiogram and Cardiac Function Levels in Patients with Unstable Angina Pectoris |
HE Zhaoguo, ZOU Yang |
The 989th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, Luoyang Henan 471000 |
|
|
Abstract 【Objective】To explore the effects of Danshen Chuanxiongqin Injection combined with Trimetazidine on electrocardiogram and cardiac function in patients with unstable angina pectoris (UAP).【Methods】A retrospective analysis was conducted on the clinical data of 106 UAP patients admitted to our hospital from January 2021 to May 2023. According to different treatment methods, they were divided into a control group and an observation group, with 53 cases in each group. The control group was treated with trimetazidine, while the observation group was treated with Danshen Chuanxiongqin Injection+trimetazidine. We compared between two groups in terms of the clinical efficacy, seizure frequency, nitroglycerin dosage, duration, cardiac function [cardiac output (CO), left ventricular ejection fraction (LVEF), stroke output (SV)], and electrocardiogram changes [ST segment depression amplitude], ST segment depression frequency, serum biochemical indicators, angiopoietin like protein 2 (Angptls2), oxidized low-density lipoprotein (ox-LDL),C1q tumor necrosis factor related protein 1 (CTRP1) and occurrence of adverse reactions.【Results】The effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the seizure frequency, nitroglycerin dosage, and duration of the two groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); CO, LVEF and SV of two sets were both higher than those before treatment, and the observation group was higher than the control group, with a statistically significant difference (P<0.05); The ST segment depression amplitude and the number of ST segment depressions of two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05); The levels of Serum Angptls2, ox-LDL and CTRP1 of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】The combination of Danshen Chuanxiongqin Injection and Trimetazidine has a good clinical efficacy in the treatment of UAP, which helps to alleviate patient symptoms, improve heart function, and has high safety.
|
Received: 24 August 2023
|
|
|
|
|
[1] 汪玮,刘志红,曾磊.不稳定型心绞痛患者外周血TGF-β1、ET-1对室性心律失常的预测价值及近期预后影响[J].中国循证心血管医学杂志,2022,14(5):624-628.
[2] 张苗,陈顺煌,张欢,等.曲美他嗪联合瑞舒伐他汀对不稳定型心绞痛患者心肌重塑及血管内皮功能的影响[J].贵州医药,2021,45(4):534-535.
[3] 周思梦,詹蔷薇.丹参川芎嗪注射液联合阿托伐他汀钙片对冠心病伴心绞痛患者脂代谢、血管内皮功能、血液流变学指标的影响分析[J].中国血液流变学杂志,2021,31(4):473-475.
[4] 张天花,付颖文.益心康泰胶囊联合比索洛尔对不稳定型心绞痛患者症状改善及心电图变化的影响[J].血栓与止血学,2022,28(3):373-375.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304.
[6] 中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:139.
[7] 成力,胡建波,李小庆.梗死前心绞痛对STEMI患者PCI后主要不良心血管事件及慢血流的影响[J].中国循证心血管医学杂志,2022,14(1):70-74.
[8] 王要鑫,刘洁云,秦雷,等.匹伐他汀联合曲美他嗪对老年不稳定型心绞痛合并2型糖尿病患者PCI术后血管内皮功能的影响[J].中国医药导刊,2022,24(2):148-151.
[9] 赖振岸,林泽辉,王明霞,等.理气化瘀祛痰法辅助曲美他嗪对稳定性心绞痛气滞血瘀兼痰湿证患者心功能及血清炎症因子的影响[J].世界中西医结合杂志,2022,17(9):1837-1842.
[10] 王晓芳,蒙婷,马伶.丹参多酚注射液联合尼可地尔治疗冠心病不稳定型心绞痛(痰瘀互结型)临床疗效及对血清学指标的影响[J].湖北中医药大学学报,2021,23(1):18-21.
[11] 杨丹,许娟娟,王璇,等.替格瑞洛联合盐酸川芎嗪对不稳定型心绞痛患者内皮细胞特异性分子-1、白介素-1β、可溶性血管细胞黏附分子1的影响[J].世界临床药物,2022,43(1):51-55.
[12] 王灿,王志荣,朱心瑶,等.不稳定型心绞痛患者血清CTRP1、ox-LDL、Visfatin水平与心功能的关系及其预后预测效能[J].山东医药,2022,62(23):61-64.
[13] 邹燕,金立伟,李佩哲.心绞痛患者血清Lp-PLA2、CTRP1、Angptls2水平及临床意义[J].中国实验诊断学,2021,25(5):705-708.
[14] 贾磊,高钊.冠心病不稳定型心绞痛合并冠脉狭窄患者CRP、Angptls2、CTRP1水平变化及临床意义[J].海南医学,2020,31(8):966-968.
[15] 陈军,谭德敏,蒙振发.丹参川芎嗪注射液联合双联抗血小板对不稳定型心绞痛患者细胞凋亡、斑块稳定性及血管内皮功能的影响[J].中国老年学杂志,2020,40(12):2477-2480. |
[1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 919-921. |
|
|
|
|